The results of this study showed that low-dose IL-2 combined with TCZ treatment could safely and effectively reduce arthritis symptoms in RA patients, promote the more stable proliferation of Tregs, and reduce the proliferation of Th2, Th17, and Th17/Treg caused by IL-2 treatment alone. The gene discussed is IL2; the disease is arthritic joint disease.